Skip to main navigation Skip to search Skip to main content

Anticoagulation in COVID-19

    Research output: Contribution to journal › Article (Academic Journal) › peer-review

    21 Citations (Scopus)
    70 Downloads (Pure)
    Original languageEnglish
    Pages (from-to)5-7
    Number of pages3
    JournalLancet
    Volume399
    Issue number10319
    Early online date15 Dec 2021
    DOIs
    Publication statusPublished - 1 Jan 2022

    Bibliographical note

    Funding Information:
    ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.

    Cite this